Individuals and groups opposed to stem cell research have dominated submissions to the Lockhart Legislative Review of Australia's stem cell legislation. [ + ]

The scene: biotechnology is the quintessential knowledge-based industry. But most of its advances have come from advancements in information technology, and how they are applied to genetic processes. Could this be a model for the biotechnology industry in NSW in 2020? [ + ]

Nucleus Network, the new umbrella name for Clinical Trials Victoria (CTV), the Centre for Clinical Studies (CCS) and its member alliances, was launched today at the organisation's facility, located adjacent to Melbourne's Alfred Hospital -- three hours after a 12-patient clinical trial finished in the same room [ + ]

Pain management company ZingoTX, a subsidiary of Eqitx (ASX:EQX) has been awarded a AUD$1.45 million AusIndustry Commercial Ready grant to support the ZingoTX drug development program over the next 12 months. [ + ]

Melbourne- and California-based ChemGenex Pharmaceuticals (ASX:CXS) posted revenues of AUD$4.1 million, up 13.9 per cent and has reduced its loss by 8.7 per cent to $4.7 million for the year ending 30 June 2005. [ + ]

Auckland biopharma Neuren Pharmaceuticals (ASX: NEU) has begun to recruit the 30 patients who will take part in its phase II pharmacokinetics and safety trial of its lead drug Glypromate. [ + ]

A handheld biosensor device that can immediately register food, water and blood contaminants will be developed with the help of a AU$774,000 Australian government grant, as part of a multi-million dollar R&D Start funding round recently announced by Federal Minister for Industry, Tourism & Resources, Ian Macfarlane.

Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has reported a loss of AUD$10.7 million for the year ended 30 June 2005, up 13 per cent from $9.5 million last year. [ + ]

Biota Holdings' (ASX:BTA) US-based CEO Peter Molloy has decided not to renew his contract in January 2006 following the company's decision to consolidate its operations back into its Melbourne facility. [ + ]

Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has secured new investment funds from a syndicate of UK investors including an undisclosed institutional group. [ + ]

Amrad (ASX:AML) has reported a healthy cash position of AUD$51.7 million and an operating loss of AUD$1.622 million for the year ended 30 June 2005, down from $3.523 million last year. [ + ]

Singapore-based generics company SciGen (ASX:SIE) has posted a net loss of SGD$5.6 million (AUD$4.43 million) for 2004-05, up 29 per cent from the previous financial year. [ + ]

Norwood Abbey (ASX:NAL) and Australian Wool Innovation (AWI) have signed an agreement to enter into phase II development of a non-surgical mulesing technology to prevent sheep flystrike using Norwood's needle-free injection technology. [ + ]

Australian corporate leader Hugh Morgan is the new chairman of Melbourne-based flu vaccine company BioDiem (ASX:BDM) which has reported an increased loss of AUD$4.2 million in 2004-05, up 32 per cent from the last financial year. [ + ]

NeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year. [ + ]